Cytek Biosciences (CTKB) announced preliminary revenue results for the fourth quarter and full year ended December 31, 2025. Cytek expects total revenue for the full year 2025 to be approximately $201 million. For the fourth quarter, the company projects revenue of approximately $62 million, growth of 8% compared to the fourth quarter of 2024.
Cytek plans to report financial results for the fourth quarter, and to provide 2026 financial guidance during its earnings call expected to be held near the end of February 2026.
In pre-market trading on NasdaqGS, Cytek Biosciences shares are up 9.7 percent to $5.98.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.